Analyzing ProKidney (PROK) and Its Peers

ProKidney (NASDAQ:PROK – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare ProKidney to similar businesses based on the strength of its analyst recommendations, institutional ownership, profitability, valuation, earnings, risk and dividends.

Valuation and Earnings

This table compares ProKidney and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ProKidney $890,000.00 -$68.99 million -1.73
ProKidney Competitors $725.56 million $8.88 million -17.98

ProKidney’s rivals have higher revenue and earnings than ProKidney. ProKidney is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares ProKidney and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProKidney -13,326.71% N/A -37.98%
ProKidney Competitors -12,519.20% -215.47% -31.42%

Volatility and Risk

ProKidney has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, ProKidney’s rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ProKidney and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney 1 0 2 1 2.75
ProKidney Competitors 9959 15361 45766 1602 2.54

ProKidney currently has a consensus price target of $10.00, suggesting a potential upside of 861.54%. As a group, “Biotechnology” companies have a potential upside of 114.65%. Given ProKidney’s stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than its rivals.

Insider & Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ProKidney beats its rivals on 8 of the 13 factors compared.

ProKidney Company Profile

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.